APA (7th ed.) Citation

CS, C., D, R., CP, V., & RC, B. (2007). Endoglin inhibits prostate cancer motility via activation of the ALK2-Smad1 pathway. Oncogene, 26(51), 7240. https://doi.org/10.1038/sj.onc.1210533

Chicago Style (17th ed.) Citation

CS, Craft, Romero D, Vary CP, and Bergan RC. "Endoglin Inhibits Prostate Cancer Motility via Activation of the ALK2-Smad1 Pathway." Oncogene 26, no. 51 (2007): 7240. https://doi.org/10.1038/sj.onc.1210533.

MLA (9th ed.) Citation

CS, Craft, et al. "Endoglin Inhibits Prostate Cancer Motility via Activation of the ALK2-Smad1 Pathway." Oncogene, vol. 26, no. 51, 2007, p. 7240, https://doi.org/10.1038/sj.onc.1210533.